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The Ink4a Tumor Suppressor Gene Product,
p19Arf, Interacts with MDM2 and Neutralizes
MDM2's Inhibition of p53
Rb and p53 (Williams et al., 1994), and mice that are Rb
(1/2) and p53 (2/2) develop a wider range of tumors
at earlier ages than mice that are either Rb (1/2) or p53
(2/2) (Williams et al., 1994). Moreover, the ability of
several viruses to transform cells in culture and cause
Jason Pomerantz,* Nicole Schreiber-Agus,*
Nanette J. LieÂ geois,* Adam Silverman,* Leila Alland,*²
Lynda Chin,*³ Jason Potes,* Ken Chen,* Irene Orlow,§
Han-Woong Lee,*# Carlos Cordon-Cardo,§
and Ronald A. DePinho*‖
tumors in mice is due to viral oncoproteins that bind to*Department of Microbiology and Immunology
and inactivate both Rb and p53 (Mahon et al., 1987;²Division of Pediatric Hematology/Oncology
Hawley-Nelson et al., 1989; Munger et al., 1989; Sy-Department of Pediatrics
monds et al., 1994). The mechanistic basis for this dual³Division of Dermatology, Department of Medicine
requirement stems inpart fromthe deactivation of a p53-Albert Einstein College of Medicine
dependent cell suicide program that would normally beBronx, New York 10461
brought about as a response to unchecked cellular pro-§Department of Pathology
liferation resulting from Rb-deficiency (Gottlieb andMemorial Sloan-Kettering Cancer Center
Oren, 1996; Ko and Prives, 1996; Levine, 1997).1275 York Avenue
p53 mutation is thought to be the most frequent ge-New York, New York 10021
netic alteration in human cancers (Hollstein et al., 1991;
Levine et al., 1991). In proliferating normal and neoplas-
tic cells, the consequences of p53 overexpression areSummary
context-dependent, resulting in either cell cycle arrest
or induction of apoptosis (Ko and Prives, 1996). TheseThe INK4a gene encodes two distinct growth inhibi-
biological end points provide a basis for p53's antionco-torsÐthe cyclin-dependent kinase inhibitor p16Ink4a,
genic actions (Eliyahu et al., 1989; Finlay et al., 1989)which is a component of the Rb pathway, and the
and have been shown to relate to its capacity to functiontumor suppressor p19Arf, which has been functionally
as a sequence-specific transcription factor (Crook et al.,linked to p53. Here we show that p19Arf potently sup-
1994; Pietenpol et al., 1994) and to interact with keypresses oncogenic transformation in primarycells and
cellular proteins. The critical role served by p53 in thesethat this function is abrogated when p53 is neutralized
diverse physiological processes necessitates that p53by viral oncoproteins and dominant-negative mutants
activity be subject to stringent multilevel regulation. Onebut not by the p53 antagonist MDM2. This finding,
crucial level of regulation involves the MDM2 protein,coupled with the observations that p19Arf and MDM2
whose direct interaction with p53 blocks p53-mediatedphysically interact and that p19Arf blocks MDM2-
transactivation (Chen et al., 1995) and targets the p53induced p53 degradation and transactivational silenc-
protein for rapid degradation (Haupt et al., 1997; Kubbu-ing, suggests that p19Arf functions mechanistically to
tat et al., 1997; Levine, 1997). MDM2 itself has beenprevent MDM2's neutralization of p53. Together, our
shown to be amplified in primary tumors (Oliner et al.,findings ascribe INK4a's potent tumor suppressor ac-
1992), toact as an immortalizing oncogene in cell culturetivity to thecooperative actions of its two protein prod-
(Finlay, 1993), and to directly repress basal transcriptionuctsand their relation to the two central growth control
(Thut et al., 1997).pathways, Rb and p53.
In human cancers, disruption of the Rb pathway can
result from inactivation of Rb itself through gene muta-Introduction
tion/deletion, viral sequestration or hyperphosphoryla-
tion (Weinberg, 1995), or through disregulation of theGrowth control in mammalian cells is accomplished
components controlling the degree of Rb phosphory-largely by the Rb protein regulating exit from the G1
lation. The latter can take place through activatingphase (Weinberg, 1995) and the p53 protein triggering
mutations in the G1-specific cyclin-dependent kinasegrowth arrest/apoptotic processes in response to cellu-
4 (CDK4) catalytic unit, up-regulation of D-type cyclinlar stress (Levine, 1997). Cross-talk between these two
levels, and/or elimination of INK4s (for inhibitors ofregulatory pathways may be mediated through the p21
cyclin-dependent kinase 4) (Sherr, 1996). The productscdk inhibitor, which is a target of p53 transactivation as
of INK4 family genes have been shown to bind to CDK4well as a factor that influences the functional status
and inhibit CDK4-directed phosphorylation of Rb (Ser-of Rb (Weinberg, 1995). An additional level of overlap
rano et al., 1993; Quelle et al., 1995a), thereby blockingbetween p53 and Rb is provided by the MDM2 protein
exit from the G1 phase of the cell cycle (Sherr, 1996).that can physically associate with both proteins and
One member of the INK4 family, INK4a, has been shownprevent their growth suppression (Momand et al., 1992;
to exhibit loss of function in a wide spectrum of tumorXiao et al., 1995). In tumorigenesis, Rb and p53 appear
types; this pathogenetic event appears to be exceededto serve collaborative roles as evidenced by the obser-
in frequency only by p53 inactivation. The basis for thevations that many tumor types exhibit mutations in both
prominence of INK4a, as opposed to other members
of the INK4 family, in tumor suppression is not fully‖ To whom correspondence should be addressed.
understood but may relate to its unusual capacity to# Present address: Department of Biochemistry and Molecular Biol-
encode two distinct proteinsÐthe cyclin-dependent ki-ogy, Seoul National University College of Medicine, Ilchun Institute
of Molecular Medicine, Seoul, Korea. nase inhibitor, p16INK4a, and a novel protein of unknown
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function, p19ARF. This special feature of INK4a results p16Ink4a, or both. As shown in Figure 1, addition of mouse
p16Ink4a induced a 1.7- to 3-fold reduction in foci num-from an unusual gene organization in which the two
ber when added to c-myc/RAS transfections (panel A,INK4a gene products are encoded by different first ex-
p16Ink4a) and failed to cause a statistically significant de-ons and alternative reading frames residing in a common
crease in E1a/RAS foci counts (panel B, p16Ink4a); thesesecond exon. The fact that both gene products are often
results are identical to our previous report for the humaneliminated or mutated in many cancers has raised ques-
p16Ink4a (Serrano et al., 1995). Since E1A inactivates thetions regarding their relative contributions to INK4a-
Rb protein, the failure of p16Ink4a to suppress E1/RASmediated tumor suppression.
transformation is as expected (Lukas et al., 1995; Med-Compelling support for p16INK4a as a critical target of
ema et al., 1995; Serrano et al., 1995). In the same co-tumorigenesis includes germline mutations/deletions
transfection experiments, addition of p19Arf resulted inexclusively affecting the p16INK4a ORF in melanoma-
marked foci reductions in c-myc/RAS (5- to 10-fold) asprone kindreds and a tumor-associated CDK4 mutation
well as E1a/RAS (4- to 5-fold) cotransfections (panelsrendering this kinase insensitive to p16INK4a inhibition
A and B, p19ARF). E1a/RAS inhibition by p19Arf was not(Zuo et al., 1996). With regard to p19ARF, although direct
further augmented by the addition of p16Ink4a (panel B,evidence linking loss of p19ARF function with human tu-
compare p19Arf and p16Ibk4a 1 p19Arf). In contrast, coaddi-morigenesis has been lacking, many INK4a mutations/
tion of p16Ink4a and p19Arf resulted in a complete inhibitiondeletions map to the exon 2 region that is shared by
of c-myc/RAS transformation. Thus, the distinct activityp19ARF, and a p19ARF-specific knockout leads to sponta-
profiles of p16Ink4a and p19Arf (i.e., E1a/Ras transfections),neous tumor formation in mice (Kamijo et al., 1997).
together with their additive effects in the c-myc/RASSome clues addressing p19ARF's mechanism of action
transfections, suggests that these proteins suppresshave been provided by the requirement for p53 in p19Arf-
neoplasia through separable but cooperative mecha-induced G1 arrest and by an absence of p53 mutations
nisms of action (see below).in postcrisis p19Arf (2/2) MEF cultures (Kamijo et al.,
1997) and in RAS-induced melanomas arising in the
Functional p53 Is Required for FullInk4a null mice (Chin et al., 1997). Additionally, studies
Oncogenic Suppression by p19Arfreported here suggest that p19Arf requires p53 function
The cell cycle inhibitory effects of p19Arf in primary MEFto suppress cellular transformation. All of these observa-
cultures have been shown to be p53-dependent (Kamijotions have led to the intriguing possibility that the INK4a
et al., 1997). To examine the possibility that p19Arf maygene is linked not only to the Rb pathway through p16INK4a
also act in a p53-dependent manner to suppress cellularbut also to the p53 pathway through p19ARF. Along these
transformation, we employed cells rendered functionallylines, our studies demonstrate that p19Arf engages the
(T-Ag or dominant-negative p53) or genetically [p53p53 pathway through physical interactions with the
(2/2)] deficient for p53 in transformation assays. TheMDM2 oncoprotein. In addition, we show that p19ARF
addition of p19Arf to T-Ag/RAS cotransfections was foundinhibits the oncogenic actions of MDM2, blocks MDM2-
to have no effect on the number of foci generated in theinduced degradation of p53, and enhances p53-depen-
REF assay (Figure 1C) or on the morphological/growthdent transactivation. Finally, we demonstrate that loss
characteristics of these foci (data not shown). Sinceof Ink4a attenuates apoptosis brought about by Rb defi-
T-Ag is known to engage many pathways beyond p53ciency. These studies provide physical and mechanistic
(Fanning, 1992; Van Dyke, 1994), we next assessed the
insight fortifying Ink4a's position at the nexus of the two
ability of p19Arf to suppress transformation in two other
most important tumor suppressor pathways governing
contexts. First, in comparison to the addition of an
the development of neoplasia and provide an explana-
empty vector control, the addition of p19Arf did not affect
tion for the frequent involvement of Ink4a in tumori-
the number of foci-generated in cotransfections of a
genesis. dominant-negative mutant form of p53 (p53KH215) and
RAS in the REF assay (Figure 1C). Second, potent p19Arf-
induced suppression of Myc/RAS foci formation was
Results observed in early passage Ink4a (2/2) mouse embry-
onic fibroblasts (MEFs), but this suppression was com-
Distinct and Cooperative Effects of p16Ink4a pletely eliminated in MEFs doubly null for Ink4a and p53
and p19ARF in the Suppression of Primary (Figure 1D). These results strongly suggest that p19Arf
Cell Transformation does not act in a nonspecific cytotoxic manner to reduce
The antioncogenic potencies of the two Ink4a gene foci formation in the Myc/RAS and E1a/RAS experi-
products were tested in the rat embryo fibroblast (REF) ments described above. Instead, these results appear to
cotransformation assay (Land et al., 1983) against vari- assign specificity to the antioncogenic actions of p19Arf.
ous oncogene combinations (e.g., Myc/RAS, E1a/RAS, More specifically, in accord with the recently reported
or SV40 Large T Antigen (T-Ag)/RAS). This approach cell cycle studies (Kamijo et al., 1997), these findings
has been used extensively to provide a quantitative support the hypothesis that p19Arf acts in a p53-depen-
measure of antioncogenic activity and allows for place- dent manner to inhibit cellular transformation.
ment of these activities along known growth control
pathways (Schreiber-Agus et al., 1995; Alland et al., p19Arf Associates with MDM2 In Vivo
1997; Lahoz et al., 1997). In the first series of experi- To gain insight into the mechanistic basis for the func-
ments, we investigated the degree of inhibition of E1a/ tional link between p19Arf and the p53 pathway, coimmu-
noprecipitation experiments were performed to assessRAS- versus Myc/RAS-induced foci formation by p19Arf,
p19Arf Blocks MDM2's Inhibition of p53
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potential physical interactions between p19Arf and p53 or
the p53-associated protein, MDM2. Since endogenous
levels of these proteins are very low in normal primary
cells (Levine, 1997), the composition of the p19Arf com-
plexes was determined following cotransfection of vari-
ous expression constructs (including one encoding a
Flag epitope-tagged p19Arf protein, p19Flag) or through
the use of different tumor cell lines expressing some or
all of these proteins. As shown in Figure 2A, IP-Western
blot assays readily detected p19Flag in anti-p53 immuno-
precipitates following cotransfection with p53, MDM2,
and p19Flag (lane 2) but not with p53 and p19Flag (lanes 3
and 4). The requirement of MDM2 overexpression to
reveal a p53±p19Flag interaction was also observed fol-
lowing either anti-p53 or anti-Flag immunoprecipitations
of metabolically labeled transfected cells (data not
shown). These results demonstrate that p53, MDM2,
and p19Flag can exist as components of a multiprotein
complex in vivo. Moreover, the requirement for abun-
dant MDM2 to detect p53±p19Flag interaction suggested
that MDM2 serves as a bridging molecule, or that MDM2
induces changes in steady-state levels of p19Flag, among
other possibilities. The possibility that MDM2 overex-
pression stabilizes the level of p19Flag was ruled out by
Western blot analysis showing equivalent levels of
p19Flag in 293T cells following transfection of MDM2 and
p19Flag or of p19Flag alone (data not shown). Moreover,
although MDM2 can target p53 for degradation in some
cell types (Haupt et al., 1997; Kubbutat et al., 1997), the
levels of endogenous p53 in 293T cells remain constant
following cotransfection and overexpression of MDM2Figure 1. p19Arf Suppression of Transformation in Primary Rodent
(data not shown) due to the presence of T-Ag (HenningCells
et al., 1997).(A) Cooperative effects of the mouse p16Ink4a and p19Arf expression
To examine more directly whether p19Flag can associ-constructs in Myc/RAS cotransformation assays. Histogram of a
ate with MDM2, coimmunoprecipitation studies wererepresentative REF cotransformation assay showing the average
number of foci per 10 cm plate following cotransfections with 2 mg conducted in metabolically labeled 293T cells and in
mouse c-myc, H-RASval12, and the various expression constructs 3T3DM (amplified for Mdm2) and SAOS2 cells (null for
listed above the error bars. p53). In the 293T cells (Figures 2B and 2C), MDM2 was
(B) Distinct actions of p16Ink4a and p19Arf expression constructs in readily detected in anti-Flag immunoprecipitates follow-
E1a/RAS cotransformation assays. The same experimental design
ing cotransfection with p19Flag and MDM2 (lane 8) butas described in (A) except that each plate was cotransfected with
not with either empty vector (lane 6), p19Flag alone (lane2 mg E1a, H-RASval12, and the various expression constructs listed.
5), or MDM2 alone (lane 7). Correspondingly, anti-MDM2In this particular experiment, the p16Ink4a transfection point exhibited
an unusually low number of foci relative to the empty vector. Al- immunoprecipitations confirmed the MDM2±p19Flag as-
though this decline is not statistically significant, in all other experi- sociation in the p19Flag and MDM2 cotransfections (lane
ments the addition of mouse p16Ink4a had no inhibition against E1a/ 12). In addition, the endogenous p19Arf bandwas present
RAS transformation, similar to our previous studies with the human in the anti-MDM2 immunoprecipitates (lane 9) and the
p16Ink4a (Serrano et al., 1995). Support for the lack of an effect also
signal intensity of this band diminished upon cotransfec-derives from the lack of additional suppression by p16Ink4a in the
tion of p19Flag (lane 12), this likely due to competition forp16Ink4a 1 p19Arf transfection point compared to p19Arf alone. The
a common binding site in the MDM2 complex. In eachgeneral cyclin-dependent kinase inhibitor p21Cip1 served as a posi-
tive control for an inhibitory agent acting downstream of Rb. of these experiments, Western blot analyses of lysates
(C) Antioncogenic activity of p19Arf in T-Ag/RAS or dominant-nega- that were run in parallel confirmed the identity of p19Flag
tive p53/RAS REF cotransformation assays. On the left, histogram of and MDM2 bands (data not shown). The interaction be-
a representative REF cotransformation assay showing the average tween p19Flag and MDM2 in 293T cells was also demon-
number of foci per 10 cm plate following cotransfections with 2 mg
strated by coimmunoprecipitation in both low- and high-each of T-Ag, H-RASval12, and empty vector or p19Arf. On the right,
stringency conditions yielding identical results (Figurehistogram showing the average number of foci per 10 cm plate
2C, lanes 18 and 19, respectively).following cotransfections with 2 mg each of p53KH215 (encoding a
dominant-negative mutant p53) and H-RASval12 with or without p19Arf. To address whether the interaction of T-Ag with MDM2
(D) Antioncogenic activity of p19ARF in Myc/RAS MEF cotransforma- and p53 (Brown et al., 1993) alters the composition of
tion assays. The early passage MEFs used for each experiment were MDM2/p53/p19Arf complexes in T-Ag-expressing 293T
either null for Ink4a (left panel) or null for both Ink4a and p53 (right cells, we examined the interaction between endogenous
panel). The bars represent the number of foci generated in the pres-
p19Arf and Mdm2 in 3T3DM cell lines. These cells do notence of p19Arf relative to control plates receiving 2 mg c-myc, 2 mg
express T-Ag but do express high levels of p19Arf (QuelleRAS, and 2 mg empty vector. These assays were performed on an
et al., 1995b) and Mdm2, the latter due to gene amplifica-Ink4a null background because wild-type MEFs do not give clear,
countable foci in Myc/RAS cotransformation assays. tion (Cahilly-Snyder et al., 1987; Fakharzadeh et al.,
Cell
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Figure 2. Analysis of the p19Arf Complex In
Vivo
(A) Coimmunoprecipitation assay with anti-
p53 antibody following transfection of the
indicated expression constructs into 293T
cells. Western blots were probed with anti-
Flag antibody (HC heavy chain, LC light chain)
(15% SDS-PAGE).
(B) 293T cells transfected with the indicated
expression constructs were metabolically la-
beled, and immunoprecipitations using anti-
Flag (lanes 5±8) or anti-MDM2 (lanes 9±
12) antibodies were performed. Precipitated
proteins were analyzed on a 4%±15% SDS-
PAGE gradient gel.
(C) Immunoprecipitation±Western blot analy-
sis of 293T lysates following transfection with
the indicated expression constructs. The ly-
sates were immunoprecipitated with the anti-
bodies indicated below the lanes, and the
blots were probed with an anti-MDM2 anti-
body (8% SDS-PAGE).
(D) Same as (C) except that lysates were de-
rived from untransfected 3T3DM cells, which
express high levels of Mdm2, p19Arf, and p53.
The asterisk marks the Mdm2 forms that do
not interact with p53. The anti-p19Arf is a rab-
bit polyclonal p19Arf antisera and is compared
with nonimmune rabbit serum (NRS) (8%
SDS-PAGE).
(E) Same as (C) except that SAOS2 cells were
used.
(F) Confocal microscopic analysis of MDM2
and p19Arf protein distribution in 293T nuclei.
The yellow signal indicates colocalization of
the two proteins. A staining pattern similar to
that observed for p19Flag in 293T cells has
been observed previously for p19Arf (Quelle
et al., 1995b), supporting that this apparent
nucleolar localization pattern is not an artifact
of overexpression or epitope tagging.
1997). Of note, 3T3DM cells express several alternatively cells. The results of these studies, as shown in Figure
3, point to a complex interaction profile in which p19Flagprocessed species of Mdm2 protein (Figure 2D, lane
20±21, p90/p85, p76/p74, and in very low amounts, engages multiple sites within MDM2. Specifically, the
p19Flag±MDM2 interaction was preserved with deletionp57) (Olson et al., 1993; Barak et al., 1994). Employing
a p19Arf-specific antibody for immunoprecipitation, abun- of the entire carboxy terminal half of MDM2 (D221-491,
lanes 12±13), but this interaction was abolished with adant Mdm2 was readily detected upon Western blotting
of the immunoprecipitates with anti-Mdm2 antibody slightly larger deletion (D155±491, compare lysate in lane
10to immunoprecipitation in lane 11). While theseobser-(lane 21), further substantiating that p19Arf and Mdm2
interact in vivo. Moreover, the p76/p74 species that vations demonstrate an essential role for MDM2 amino
acid residues 154±221 in p19Arf binding, an internal dele-lacks the N-terminal p53 binding domain (Olson et al.,
1993) is also present in the immunoprecipitates (lane tion mutant of these residues was still capable of p19Arf
association in the two cell types (D155±221, lanes 6±721, asterisk marks the p76/p74 forms of Mdm2 that do
not interact with p53), suggesting that p19Arf can interact 293T, lanes 8±9 SAOS2). The persistent binding of the
D155±221 mutant may reflect additional points of con-with Mdm2 independent of Mdm2's interaction with p53.
To confirm this point, anti-Flag immunoprecipitation fol- tact in the carboxyl terminus of MDM2 that cooperate in
p19Arf binding. This view is supported by the diminishedlowing cotransfection of p19Flag and MDM2 into p53 null
SAOS2 cells yielded abundant MDM2 signal (Figure 2E, interaction between p19Flag and the D221±491 mutant in
SAOS2 cells (compare lanes 12 and 13 to lanes 14 andlane 26). Finally, confocal microscopic analysis of the
intracellular distribution of each protein demonstrated 15) and also suggests the participation of bridging mole-
cules in 293T that facilitate the p19Flag±MDM2 interactionidentical subnuclear localization patterns for p19Arf and
MDM2 in both 293T and 3T3DM cells (Figure 2F, 293T (e.g., p53, T-Ag, etc.). Taken together, the carboxy-ter-
minal localization, coupled with the ability of a p53-cells shown).
Next, a series of plasmids encoding full-length MDM2 binding-deficient mutant of MDM2 to remain competent
for p19Arf binding (lane 1), suggests that p19Arf's effectsor various mutant derivatives was tested for the ability
to associate with Flag-tagged p19Arf by coimmunopreci- upon known properties of MDM2 or p53 (see below)
likely do not result from a disruption of the physicalpitation/Western blotting analyses in 293T and SAOS2
p19Arf Blocks MDM2's Inhibition of p53
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Figure 3. Localization of p19Arf Interaction
Region of MDM2
(A) Graphic representation of the full-length
MDM2 protein (top) and MDM2 deletion mu-
tants. The known structural motifs and func-
tional domains of MDM2 are indicated. With
regard to the D1±58 mutant, previous studies
have determined that these sequences are
essential for MDM2 interaction with p53 (Mo-
mand et al., 1992; Oliner et al., 1993; Kussie
et al., 1996).
(B) Western blot analysis of lysates (lanes 2,
4, 6, 8, 10, 12, and 14) and of anti-Flag immu-
noprecipitates (lanes 1, 3, 5, 7, 9, 11, 13, and
15) following transient transfection of the indi-
cated expression constructs into 293T cells
(lanes 1±7 and 10±13) or SAOS2 cells (lanes
8±9 and 14±15). Asterisks denote the MDM2
band of interest in each immunoprecipitate.
Lanes containing lysate demonstrate that the
transfected MDM2 and its mutant derivatives
are expressed at high levels. Note the ab-
sence of an MDM2 band in the anti-Flag pre-
cipitates after transfection of D155±491 and p19Flag. The nuclear localization of each mutantprotein was confirmed by insitu immunohistochemis-
try (data not shown). The Western blots were probed with anti-MDM2 monoclonal antibody directed to an epitope (aa 26±168) present within
all of the MDM2 proteins used in this assay. Lanes 1±9, 8% SDS-PAGE. Lanes 10±15, 14% SDS-PAGE. HC, heavy chain. LC, light chain.
association between MDM2/p53 by p19Arf. Further sup- this study, HeLa cells were transiently transfected with
the various expression constructs listed in Figure 4B,port that p19Arf and p53 interact with nonoverlapping
and the levels of p53 were examined by Western blotregions of MDM2 comes from the observations that
analysis. As reported previously (Haupt et al., 1997),p19Arf and p53 can coexist in MDM2 complexes and that
p53 steady-state levels were markedly reduced in cellsp53 immunoprecipitations followed by Western analysis
cotransfected with p53 and MDM2 as opposed to p53for MDM2 showed similar levels of MDM2 relative to
alone (Figure 4B, top panel, compare lanes 2 and 3).lysate in the presence or absence of p19Arf (data not
When p19Arf was added to the p53 1 MDM2 cotransfec-shown). These conclusionsare consistent with data pre-
tions, a striking restoration in p53 levels was observedsented in the accompanying paper (Zhang et al., 1998,
(lane 4). Equal loading of protein was confirmed by re-this issue of Cell), which demonstrate that p19ARF can
probing the blots with an anti-Flag antibody, which de-associate with the carboxy-terminal 284 amino acids of
tects a nonspecific background band (NSFE) (Figure 4B,MDM2.
bottom panel) as well as by Ponceau red staining of
blots (data not shown). The precise mechanism throughFunctional Relationship of p19Arf to MDM2 and p53
which p19Arf operates to interfere with MDM2-inducedThe physical association between p19Arf and MDM2 es-
degradation is not known. Nevertheless, it is interestingtablishes a clear connection between a product of the
that MDM2 induces a ladder of more slowly migratingInk4a gene and the p53 pathway. To understand the
bands of p53 (Figure 4C, lane 1), thought to representfunctional implications of the p19Arf±MDM2 interaction,
ubiquitinated forms of p53 bound for proteasomal deg-we assessed the capacity of p19Arf to (1) inhibit MDM2
radation (Haupt et al., 1997; Kubbutat et al., 1997). Thiscotransformation activity, (2) block MDM2-induced deg-
ladder is significantly reduced in the presence of abun-radation of p53, and (3) enhance p53-related activities
dant p19Arf (Figure 4C, lane 2), suggesting that p19Arf
such as transcription and apoptosis.
inhibits polyubiquitination of p53 triggered by MDM2.
Transformation Studies
Loss of this MDM2-induced ladder was also observed
For the MDM2 transformation studies, we took advan- after transfection of p19Arf, p53, and MDM2 into two
tage of the capacity of MDM2 to cooperate with acti- other cell lines, H1299 and SAOS2 (data not shown).
vated RAS to effect the malignant transformation of early Although our studies strongly suggest that p19Arf blocks
passage REFs (Finlay, 1993). In four independent experi- MDM2-induced degradation of p53, they do not exclude
ments, we observed that the addition of p19Arf to MDM2/ other possibilities such as p19Arf stabilizing p53 in an
RAS cotransfections resulted in a dramatic reduction in MDM2-independent manner.
foci numbers, e.g., 40 foci versus 3 foci (Figure 4A). Regulation of p53 Transactivation Activity
Moreover, compared with MDM2/RAS and vector con- Enforced expression of p19Arf in primary mouse cells
trols, the MDM2/RAS-transformed foci emerging in the results in the induction of p21Cip1 (a p53-responsive gene;
p19Arf cotransfections exhibited a less transformed mor- El-Deiry et al., 1993), but only if these cells possess
phology (data not shown). functional p53 (Kamijo et al., 1997; J. P. and R. A. D.,
p53 Protein Stability Studies unpublished data). These results suggest that p19Arf can
Next, we examined the consequences of p19Arf over- enhance the transactivation activity of p53 (Kamijo et
expression on a key biochemical property of MDM2, al., 1997), perhaps through its ability to counteract
namely MDM2's ability topromote the rapid degradation MDM2. To test this directly, SAOS2 cells were trans-
fected with a CAT reporter bearing multimerized p53of p53 (Haupt et al., 1997; Kubbutat et al., 1997). For
Cell
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endogenous MDM2 levels resulting from exogenous p53
expression (data not shown). As reported previously
(Momand et al., 1992; Brown et al., 1993), addition of
MDM2 to the p53 cotransfections led to a decrease in
reporter activity (compare lanes 6 and 7 with lanes 2
and 3), and this effect was abolished with the addition
of p19Arf (lanes 8 and 9).
In light of the data presented above, enhanced p53
transactivation could result from increased p53 levels
due to p19Arf-induced stabilization of p53. However, the
findings that overexpression of p19Arf leads to stabilized
p53 complexes, which also contain MDM2 (Figure 2),
and that MDM2 binds to and masks the p53 transactiva-
tion domain raises questions as to how p53 transacti-
vation can be restored by p19Arf in the setting of high
levels of MDM2. Among several possibilities are that a
subset of transactivation domains in the stabilized p53
tetramer is not bound by MDM2, that p19Arf may function
to block MDM2-induced repression of basal transcrip-
tion, or that p19Arf activates p53 transactivation in an
MDM2-independent manner. The resolution of this point
will require further analysis in vitro. In summary, these
results demonstrate that p19Arf can enhance a key func-
tion of p53, its capacity to function as a sequence-
specific transcription factor.
Ink4a-Deficiency Attenuates Apoptosis In Vivo
The observed effects of p19Arf on p53 dependent trans-
activation (this study) and gene expression (Kamijo etFigure 4. Effect of p19ARF on MDM2-Related Functions
al., 1997), and the established importance of p53 in apo-(A) A representative MDM2/RAS cotransformation experiment com-
paring transformed foci counts in MDM2/RAS cotransfections re- ptosis prompted us to assess whether loss of p19Arf may
ceiving either empty vector, p16Ink4a, or p19Arf. affect the degree of apoptosis in vivo. We have shown
(B) Top panel, Western blot analysis of HeLa cell lysates probed previously that the developing mouse lens represents
with anti-p53 antibody (Ab-1 Calbiochem) following transfection of
an ideal system for such an analysis since loss of Rbthe indicated expression constructs. Middle panel, Western blot of
function therein is associated with unchecked prolifera-the same lysates probed with an anti-MDM2 antibody. Note induc-
tion and apoptosis in lens fiber cells, and this apoptotiction of endogenous MDM2 upon transfection of p53. The very mod-
est reduction in MDM2 levels observed upon addition of p19ARF response is highly dependent upon p53 (Morgenbesser
(lanes 3 versus 4) is not likely to account for the p19ARF effect since et al., 1994). As an indirect assessment of p19Arf effects
MDM2 levels are greatly increased over those observed in the p53- upon this phenotype, we compared rates of proliferation
alone transfections (compare lanes 4 and 2). Bottom panel, Western
and apoptosis in embryos singly null for Rb or doublyblot probed with anti-Flag antibody showing a nonspecific cross-
null for Rb and Ink4a. Since p16Ink4a is believed to bereacting Flag epitope (NSFE) used as a loading control.
without effect when Rb is absent, the doubly null lenses(C) Higher molecular weight forms of p53 that are induced by MDM2
and thought to represent polyubiquitinated p53 targeted for protea- were taken to be the functional equivalent of Rb (2/2),
somal degradation. Note that there is a decrease in these bands p19Arf (2/2) lenses.
upon addition of p19Arf. In this particular experiment, visualization Histological analyses of more than 15 Rb (2/2) and
of these p53 bands is facilitated by transfection of higher amounts
Rb (2/2), Ink4a (2/2) lenses revealed a clear increaseof p53, use of two different anti-p53 antibodies (DO-1 and 1801),
in the number of nuclei compared with age-matchedand film overexposure.
wild-type lenses (Figure 5A, compare panels b and c(D) Top panel, p53-dependent CAT reporter assays documenting
the effects of p19ARF, MDM2, or both on p53 transactivation activity. with a). Moreover, doubly null lenses had a 25%increase
Amounts loaded are normalized for transfection efficiency. For these in the number of nuclei over Rb (2/2) only lenses. While
SAOS2 transfections, the amounts of DNA used were either 0.2 or the lens fiber region of normal or Ink4a (2/2) lenses
0.5 mg for p53 and 2 mg each for MDM2 or p19Arf. Bottom panel,
does not exhibit proliferative activity (Morgenbesser ethistogram representation of p53 CAT activities as determined by
al., 1994) (Figure 5A, panel d, Ink4a (2/2) not shown),phosphorimager quantitation of signal intensities.
inappropriate cell cycle progression was confirmed
throughout the lens fiber region of Rb (2/2) and Rb
(2/2), Ink4a (2/2) lenses by the large number of cellsbinding sites in its promoter and with a combination of
expression constructs listed in Figure 4D. Since these staining positive for 5-bromo-29-deoxyuridine (BrdU) in-
corporation (Figure 5A, panelse and f). When normalizedcells are null for p53, CAT activity was detected only in
the presence of transfected p53 (compare lane 1 with to the total number of nuclei, the degree of BrdU incor-
poration in Rb (2/2) and doubly null lens fiber cells waslanes 2 and 3). Transfection of p19Arf resulted in a further
increase in reporter gene activity (lanes 4 and 5), an very similar in age-matched lenses (Figure 5B, left panel,
p , 0.001). In contrast, when lens fiber cell apoptosisincrease that takes place in the presence of detectable
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Figure 5. Effect of Ink4a Deficiency on Proliferation and Apoptosis in the Rb-Deficient Lens In Vivo
(A) Representative sections of age-matched lenses showing morphology by Hand E stain, proliferation by BrdU incorporation, and apoptosis
by TUNEL assay in E14.5 wild-type (a, d, and g), Rb (2/2) (b, e, and h) and Rb (2/2), Ink4a (2/2) (c, f, and i) lenses. The lenses are oriented
with the anterior epithelium facing the lower left corner and the lens fiber region facing the upper right corner. TUNEL-positive nuclei are
stained brown by HRP reaction.
(B) Left panel, quantitative comparision of S phase nuclei (BrdU-positive) relative to the total number of lens fiber nuclei in E13.5 and E14.5
Rb (2/2) (closed) and Rb (2/2), Ink4a (2/2) lenses (striped) (data compiled from examining 332 sections from 19 embryos). Right panel,
Quantitative comparision of apoptotic nuclei (TUNEL-positive) relative to the total number of lens fiber nuclei in E13.5 and E14.5 Rb (2/2)
(closed) and Rb (2/2), Ink4a (2/2) lenses (striped) (data compiled from examining 174 sections from 13 embryos).
was measured, the number of TUNEL-positive nuclei and tumor suppressor that exerts its actions upstream
of p53 (Kamijo et al., 1997; Chin et al., 1997; Quelle etwas significantly and consistently reduced in the doubly
null lenses relative to that present in the Rb-deficient al., 1997). Here we refine this connection between p19Arf
and the p53 pathway by demonstrating that p19Arf physi-lenses (Figure 5A, compare panels h and i; Figure 5B,
right panel). These studies show that the efficient execu- cally associates with MDM2 in vivo and blocks MDM2-
induced degradation of p53. The end result of thesetion of an apoptotic response known to be dependent
upon p53 requires full Ink4a gene function. The dual actions appears to be the enhancement of p53-related
functions such as transactivation (reporter assays, Fig-elimination of both Ink4a gene products precludes a
definitive assignment to p19Arf since it remains theo- ure 4D), growth inhibition (Kamijo et al.,1997), and possi-
bly apoptosis (lens studies, Figure 5) (see model in Fig-retically possible that p16Ink4a may play a role in the
apoptotic process through an Rb-independentpathway. ure 6B). We believe that our studies provide genetic
evidence, in addition to physical data, that p19Arf actsHowever, these findings may explain how p19Arf func-
tions as a suppressor of neoplasia, namely through its primarily on the level of MDM2 rather than p53. The
conceptual basis for this argument rests on the fact thatcapacity to enhance the p53-mediated elimination of
inappropriately cycling cells in vivo. although MDM2 overexpression acts to neutralize p53,
p19Arf can still inhibit oncogenesis in this setting (Figure
4A). In contrast, other oncoproteins that can neutralizeDiscussion
p53 render cells refractory to p19Arf suppression (Figure
1B). Thus, we propose that either (1) p19Arf can interfereRecent studies in cell culture and with knockout mouse
models have determined that the second product of the with the ability of MDM2 to neutralize p53 (Figure 6B) or
(2) p19Arf can affect as yet undetermined MDM2-specificInk4a locus, namely p19Arf, functions as a potent growth
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among the CKIs with respect to tumorigenesis? In es-
sence, two functionally distinct tumor suppressor path-
ways can be disabled by a single mutational event at
the INK4a locus, this by virtue of its unusual genetic
organization. Stated differently, INK4a's potent tumor
suppressor activity likely results from its ability to en-
code two unrelated antioncogenic proteins with cooper-
ating modes of action (Figure 6A).
Basedupon the documentedgrowth-arresting activity
encoded by the INK4a gene products (Serrano et al.,
1993; Quelle et al., 1995b) and the reduction in apoptosis
in the lenses doubly null for Rb and Ink4a (see Figure
5, above), we suggest that the mechanisms of tumor
suppression by INK4a parallel those established for Rb
and p53. Specifically, the collaborative consequences
of loss of p16INK4a and p19ARF are deregulated cell prolifer-
ation as well as deactivation or attenuation of p53-
dependent apoptosis, which normally serves topromote
the efficient elimination of these premalignant cycling
cells. In agreement with this hypothesis is the observa-
tion that tumors arising in Ink4a-deficient mice exhibit
high proliferative indices and very low rates of apoptosis
despite an intact p53 gene (C. C.-C. and R. A. D., unpub-
lished data).
One prediction of this hypothesis is that tumors defi-
cient for both p16INK4a and p19ARF would be less likely
to harbor Rb or p53 mutations. Furthermore, p19ARF-
Figure 6. One Gene±Two Products±Two Pathways Hypothesis sparing INK4a mutations could be associated with alter-
(A) Functional relationship of the INK4a gene products, p16INK4a and ations involving other components of the p53 pathway
p19ARF, and the Rb and p53 tumor suppressors. (e.g., MDM2 gene amplification or loss of p53 function).(B) Proposed mechanism for p19ARF's enhancement of p53-related
It is important to emphasize that elimination of p19ARFfunctions.
may not preclude p53 mutation since p19ARF tumor sup-
pressor activities are unlikely to overlap fully with those
transformation functions beyond those regulating p53 of p53. This lack of equivalence is made evident by the
levels and activity. The latter, although formally possible, much higher level of genetic instability in p53 (2/2)
appears less likely in light of mouse knockout studies MEFs compared with Ink4a (2/2) MEFs (Kamijo et al.,
suggesting that MDM2 functions primarily (if not exclu- 1997; N. J. L. and R. A. D., unpublished data) and by
sively) as a modulator of p53 function (Joneset al., 1995). the higher rate of spontaneous tumor formation in p53
Regardless of the precise mechanism, the physical and (2/2) mice versus Ink4a (2/2) mice (Jacks, 1994; Ser-
functional link forged between p19Arf and the p53 path- rano et al., 1996). In the lens, the level of reduction in
way, along with the previously established one between apoptosis achieved with loss of Ink4a function was less
p16Ink4a and Rb (Serrano et al., 1993; Quelle et al., 1995a) than that reported previously with loss of p53 (Morgen-
provides for a ªone gene±two products±two pathwaysº besser et al., 1994): reduction of 50%±60% for Rb (2/2),
hypothesis (Figure 6A) that can explain (1) the exceed- Ink4a (2/2) versus 75%±85% for Rb (2/2), p53 (2/2).
ingly high rate of INK4a gene deletion in many human Notwithstanding, loss-of-function mutations of p19ARF
tumors and their derivative cell lines (Kamb et al., 1994) would be predicted to decrease the frequency of tumor-
and in mouse melanomas (Chin et al., 1997) and (2) associated p53 mutations. As such, we reexamined re-
the strong connection between tumorigenesis and the ported INK4a and p53 mutations in the same human
INK4a gene as opposed to other genes encoding cyclin- cancers (Gruis et al., 1995; Newcomb et al., 1995; Bren-
dependent kinase inhibitors (CKIs), such as INK4b, ner et al., 1996; Hangaishi et al., 1996; Heinzel et al.,
p21CIP1, and p27KIP1 (Cordon-Cardo, 1995). Specifically, 1996; Kinoshita et al., 1996). These tumor types included
mice lacking Ink4b exhibit a very low incidence of melanoma, carcinomas (bladder, oral, and lung carcino-
spontaneous tumor formation (E. Latres, C. C.-C., and mas), and various lymphoid neoplasms (B-cell chronic
M. Barbacid, unpublished data); p21Cip1-deficient mice lymphocytic leukemia, and Hodgkin's and Non-Hodg-
remain tumor-free (Elledge et al., 1996); and although kin's lymphomas). This analysis demonstrated a recipro-
p27Kip1-deficient mice can develop intermediate lobe pi- cal relationship between p53 and p19ARF mutational
tuitary hyperplasia or adenoma, these neoplasms rarely events, as INK4a-deficient (p16INK4a 1 p19ARF) cancers
progress to malignant pituitary tumors (Elledge et al., rarely exhibited p53 mutant products (Gruis et al., 1995;
1996). Similarly, in human cancers, the frequent alter- Newcomb et al., 1995; Brenner et al., 1996; Hangaishi
ation of INK4a contrasts sharply with an overall lower et al., 1996; Heinzel et al., 1996; Kinoshita et al., 1996).
rate of INK4b mutation/deletion (Cordon-Cardo, 1995) In 518 tumors analyzed, the mutation rates were 18%
and infrequent mutations in p21CIP1 and p27KIP1 (Cordon- for p16INK4a, 14% for p53, and 4% for both. INK4a point
mutations that result in single amino acid changes in theCardo, 1995). What makes the INK4a gene so unique
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by standard PCR and utilization of internal restriction enzyme sites.p16INK4a ORF were reanalyzed to determine the genetic
Specifically, an XbaI site just 59 to bases encoding amino acid 155status of the p19ARF ORF. Only 9 (,2%) of 405 evaluable
was ligated in-frame to a sequence-verified PCR-generated frag-cases harbored both p53 and p19ARF mutations. Since ment containing the 59 engineered XbaI site and beginning with
all nine cases also had alterations in p16INK4a, it remains amino acid residue 221 (the oligomers used are 59-CGCCATCTAGA
possible that p19ARF mutation was incidental to that of CCGGATCTTGATGCTGGT-39 and 59-CGAAGGGCCCAACATCTG-
39). The 39 end of this PCR fragment was fused in-frame with thep16INK4a in those tumors. In fact, the most common point
remainder of the MDM2 ORF via a unique ApaI site. The final ligationmutation in the p19ARF reading frame (a P93L substitu-
was performed in the parental pCHDM1Avector in order to reconsti-tion; Quelle et al., 1995b) has been shown by us to be tute the MDM2 ORF minus sequences encoding amino acids 156±
functionally indistinguishable fromwild-type p19ARF. This 221. SAOS2 cells (5 3 106 per 10 cm plate in DME supplemented
is evidenced by the facts that the p19Arf(P93L) mutant with 10% fetal bovine serum, 5% calf serum, glutamine, andantibiot-
ics) were transfected by a modified calcium phosphate method asis fully active in suppressing Myc/RAS and MDM2/RAS
for the CAT assays (see below) and then processed as for 293Tsin the REF assay and in stabilizing p53 in the presence of
under low-stringency conditions. Untransfected 3T3DM cells werehigh MDM2 levels (data not shown). These observations
lysed in a low-stringency buffer as above. Protein (1.6 mg) was
point to the need for a revisited analysis of mutations immunoprecipitated using 150 ml anti-MDM2 (2A10) (Olson et al.,
for p19ARF, p16INK4a, p53, and MDM2 in the same tumor 1993) and protein G agarose or anti-p19Arf (4 ml) with protein A
agarose for 1 hr. Western blots were probed with 2A10 1:100 tosamples. Although available data (Kamijo et al., 1997;
detect endogenous MDM2. The anti-p19Arf antibodies were providedthis paper) do not permit us to conclude that p19ARF
by Charles Sherr (St. Jude's). For p53 degradation studies, 6 3 105and p53 mutations are mutually exclusive, the distinctly
HeLa cells or H1299 cells maintained in DME supplemented with
uncommon occurrence of comutation of p53 and p19ARF 10% fetal calf serum and antibiotics, or 5 3 106 SAOS2 cells main-
supports the view that they operate through common tained as for CAT assay were transfected by the calcium phosphate
method, with 2 mg pC53SN3 (R. Tjian), 5 mg MDM2, and/or 5 mggenetic pathways for at least a significant portion of
p19Flag and harvested in RIPA buffer 24 hr after transfection. Westerntheir tumor suppressor activity.
blots were probed with anti-p53 Ab-1 (Figure 4B), or a mixture of
monoclonal p53 antibodies DO-1 and 1801 (Santa Cruz) all at 1:100
Experimental Procedures dilution (Figure 4C). For confocal analysis, 293T cells were seeded
on gelatin-coated glass cover slips at a density of 130,000 cells per
Expression Constructs and REF Cooperation Assays 2 cm well. The cells were transfected with Flag-tagged p19Arf and
Expression constructs encoding mouse p16Ink4a and p19Arf were gen- human MDM2 constructs as above 24 hr after seeding. Forty-eight
erated by placing the complete ORFs derived from their respective hours posttransfection, cells were fixed in 2% paraformaldehyde
cDNAs (Schreiber-Agus et al., 1994) in the sense orientation relative for 10 min, washed in PBS, permeablized in 1% Triton X-100 for 10
to two tandemly repeated Moloney murine leukemia virus (MuLV) min, blocked with 3% milk in PBS for 30 min, and incubated in
long terminal repeats in the pVNic vector (Schreiber-Agus et al., primary antibody diluted in blocking solution overnight at 48C. For
1997). Expression constructs for c-myc, mutant H-RAS, and E1a Flag-tagged p19Arf, M2 antibody, (Kodak) was used at a concentra-
have all been described previously (Schreiber-Agus et al., 1997), tion of 5 mg/ml. Anti-MDM2 Ab-1 (Calbiochem) was diluted 1:10.
and theCMV-driven expression construct encoding the KH215 dom- Following this incubation, cells were washed in PBS and incubated
inant-negative mutant form of p53 (Gruis et al., 1995) has been in secondary Ab for 1 hr. The secondary antibodies (Southern Bio-
described previously. To perform the rat embryo fibroblast (REF) technology) were anti-IgG2a-Texas red for Flag and anti-IgG1-FITC
for MDM2. All incubations except for primary antibody were at roomcooperation assays, early passage cultures of REFs were prepared
temperature. Finally, cells were washed, and cover slips wereand cotransfected as described previously (Schreiber-Agus et al.,
mounted in 1:1 glycerol:PBS for viewing on a Bio-Rad MR600 laser-1997) with DNA mixtures containing 2 mg each of the relevant ex-
scanning confocal microscope.pression constructs plus the corresponding amount of carrier DNA,
for a total of 30 mg DNA. At 9±12 days posttransfection, foci were
TUNEL and BrdU Assaysscored visually and confirmed by microscopic examination to be
TUNEL and BrdUincorporation assays wereperformed as describedtransformed morphologically. For the MEF assays, early passage
elsewhere (Morgenbesser et al., 1994) on 3 mM paraffin-embeddedMEFs were prepared from day 13.5 embryos minced and seeded
lens sections prepared as described elsewhere (Morgenbesser etinto 10 cm plates. The following day, cells were split 1:3 and frozen
al., 1994).upon reaching confluency (z24 hr). MEFs were thawed and
transfected according to the REF assay protocol.
CAT Reporter Assays
Cultures of SAOS2 cells were maintained as above and transfectedProtein Analysis
by calcium phosphate using the same amounts of DNA as in p53293T cells (1.4 3 106 per 10 cm plate in DME supplemented with
degradation studies and immunoprecipitation assays, plus 2.5 mg
10% fetal bovine serum, glutamine, and antibiotics) were trans-
PG13CAT, with DMSO shock, 5 hr after addition of the precipitate
fected under serum and antibiotic free conditions with 3 mg each (Brown et al., 1993). Cells were harvested 48 hr postshocking, and
of the appropriate expression constructs shown in Figures 2 and 3, CAT reporter activity was assayed by acetylation of 14C-labeled
and 80 mg of Lipofectamine reagent (GIBCO BRL). For Figure 2B, chloramphenicol as reported previously (Gorman et al., 1982), ex-
cells were metabolically labeled using the EXPRESS 35S protein- cept that the extracts were incubated at378C for 45 min, the samples
labeling mix (Dupont-NEN) for 7 hr before collection. Immunoprecip- were resuspended in 20 ml of ethyl acetate, and the quantities of
itations under low-stringency conditions (1% NP-40, 10% glycerol, protein assayed for CAT were approximately 30 mg per point. Trans-
10 mM NaF, 50 mM b-glycerophosphate, protease inhibitors in PBS) fection efficiencies were determined by addition of 2 mg of human
were performed as described previously (Schreiber-Agus et al., growth hormoneplasmid to each transfection point and assaying the
1997) using anti-p53 Ab-6 conjugated beads (Calbiochem), and anti- media for human growth hormone by radioimmunoassay (Nichols
Flag M2 (Kodak) and anti-HDM-2 Ab-1 (Calbiochem) antibodies. For Institute) just before cell lysis. Signal was quantitated using Phos-
high-stringency immunoprecipitations, RIPA buffer (150 mM NaCl, phorQuant software. The reporter construct, detailed elsewhere
1%NP-40, 0.5% deoxycholate, 0.1% SDS, and 50 mM Tris) was (Bartkova et al., 1996), was the PG13-CAT construct bearing a pro-
used. To construct the Flag epitope-tagged p19Arf construct, PCR moter with multiple copies of the p53 consensus binding site.
was used to fuse in-frame Flag epitope sequences at the 39 end of
the p19Arf ORF, and the sequence-verified PCR product was cloned Acknowledgments
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